Wits Reproductive Health and HIV Institute
11
0
0
9
Key Highlights
Risk & Performance
Pipeline Risk Assessment
Pipeline Risk Assessment
Based on historical performance
High Risk
Score: 75/100
18.2%
2 terminated/withdrawn out of 11 trials
81.8%
-4.7% vs industry average
9%
1 trials in Phase 3/4
44%
4 of 9 completed trials have results
Key Signals
Enrollment Performance
Analytics
Activity Timeline
Global Presence
Clinical Trials (11)
The PrEP (Pre-exposure Prophylaxis) SMART Study
Role: collaborator
Evaluation of Pharmacokinetic Drug-drug Interactions Between Hormonal Contraceptives and Doravirine-containing ART Among Women Living With HIV in South Africa
Role: collaborator
The CATALYST Study
Role: collaborator
Plan and Pledge, HIV Self-testing in South Africa
Role: collaborator
CHARISMA Expansion Study
Role: collaborator
Incentives to Promote Sustained Linkage to HIV Care
Role: collaborator
The Intensified Treatment Monitoring Strategy to Prevent Accumulation of Drug Resistance (ITREMA) Trial
Role: collaborator
The Prevention Options for Women Evaluation Research (POWER) Cohort
Role: collaborator
Smart Linkage-to-HIV Care Via a Smartphone App
Role: collaborator
The Evidence for Contraceptive Options and HIV Outcomes Trial
Role: collaborator
Clinical Evaluation of Adjusted Doses of Darunavir/Ritonavir With Rifampicin in HIV-infected Volunteers
Role: collaborator
All 11 trials loaded